LIFR also known as CD118 (Cluster of Differentiation 118), is a subunit of a receptor for leukemia inhibitory factor. The leukemia inhibitory factor (LIF) is a polyfunctional cytokine that affects the differentiation, survival, and proliferation of a wide variety of cells in the adult and the embryo. LIF action appears to be mediated through a high-affinity receptor complex composed of a low-affinity LIF binding chain (LIF receptor) and a high-affinity converter subunit, glycoprotein 130 (IL6ST, gp130). Both LIFR and gp130 are members of a family of cytokine receptors that includes components of the receptors for the majority of hematopoietic cytokines and for cytokines that affect other systems, including the ciliary neurotrophic factor, growth hormone and prolactin.
Background References
1. Viswanadhapalli S et al. Targeting LIF/LIFR signaling in cancer. Genes Dis. 2021 Apr
2. Bai Z et al. Long Noncoding RNA LIFR-AS1: A New Player in Human Cancers. Biomed Res Int. 2022 Jan
Western blot analysis of LIFR on different lysates with Rabbit anti-LIFR antibody (HA723028) at 1/2,000 dilution.
Lane 1: HeLa cell lysate Lane 2: PANC-1 cell lysate Lane 3: T-47D cell lysate (negative) Lane 4: MDA-MB-231 cell lysate Lane 5: HCT 116 cell lysate Lane 6: RD cell lysate
Lysates/proteins at 20 µg/Lane.
Predicted band size: 124 kDa Observed band size: 180 kDa
Exposure time: 46 seconds; ECL: K1802;
4-20% SDS-PAGE gel.
Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody (HA723028) at 1/2,000 dilution was used in 5% NFDM/TBST at 4℃ overnight. Goat Anti-Rabbit IgG - HRP Secondary Antibody (HA1001) at 1/50,000 dilution was used for 1 hour at room temperature.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"